MTOR and neoplasm: OPi inhibited oxidative phosphorylation and tumor growth, correlating with decreased MAPK and mTOR complex I activity, increased glucose incorporation into glycolysis, reduced mitochondrial TCA cycle activity, and diminished cellular nucleotide and amino acid pools, highlighting its potential as a therapeutic strategy to overcome intrinsic and acquired resistance to MAPKi [50].